Small-Molecule Drugs
Apomorphine
Last reviewed: 2026-11-19
Evidence status & limitations
FDA-approved Parkinson’s disease products do not establish FDA approval for sexual-health indications.
Regulatory status
FDA approval applies only to the named products and indications below. It does not approve every formulation or other use.
Apokyn · Parkinson’s Disease
Acute intermittent treatment of hypomobility or off episodes associated with advanced Parkinson’s disease.
Authoritative label recordOnapgo · Parkinson’s Disease
Treatment of motor fluctuations in adults with advanced Parkinson’s disease. This is a separate product-specific indication from Apokyn.
Authoritative label record
Status as of 2026-11-19. Regulations change. Check FDA.gov for current information.
WADA prohibited status: current list and contextKnown risks & open questions
Nausea, hypotension, somnolence and impulse-control effects are documented concerns.
Key sources
Targeted factual corrections checked against the sources below on November 19, 2026. This is not an exhaustive systematic review; discovery dates, exact molecular forms and current labels require separate verification.
Related compounds
- Finasteride
Same scientific class · A small chemical molecule, not a peptide. · FDA-approved for specific indications
- Metformin
Same scientific class · A small chemical molecule, not a peptide. · FDA-approved for specific indications
- Methylthioninium chloride
Same scientific class · A small chemical molecule, not a peptide. · FDA-approved for specific indications
- Minoxidil
Same scientific class · A small chemical molecule, not a peptide. · FDA-approved for specific indications
- Omeprazole
Same scientific class · A small chemical molecule, not a peptide. · FDA-approved for specific indications